EN DE

MeHow Innovative Ltd (301363) Fair Value & Analysis

Healthcare · CN · Market cap 14.6B CNY

MI MeHow Innovative Ltd 301363 · SHE
Price¥17.26
Fair Value¥5.93
Upside-65.6%
Quality48/100
Watch MeHow Innovative Ltd for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Solidly profitable · 16.6% net margin
Low debt · negative free cash flow
1.08% dividend yield
Mixed vs. peers (6/13)
Moderate moat 53/100
Evidence: Medium Range ¥4.16 – ¥7.72 Share as image

Fair value as of: Jul 9, 2026

From 14 valuation models · updated 32 days ago

Share price −13.7% over the past month.

Below-average quality, and screening another 66% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥7.72). The favourable scenario is already priced in.
  • Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (¥4.16 to ¥7.72) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (4 years)

¥30.07 ¥11.09 Fair Value ¥5.93 Oct 2022 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

46‑month range ¥11.09 – ¥30.07 · fair‑value band ¥4.16 – ¥7.72 · the ¥17.26 price screens above the ¥5.93 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

MeHow Innovative Ltd (301363) currently trades at ¥17.26, while our model-based Fair Value estimate is ¥5.93, implying the stock looks roughly 65.6% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, MeHow Innovative Ltd generated revenue of 1.7B CNY at a net margin of 16.6%. Revenue grew 36.3% year over year. It earns a return on equity of 7.9%. The stock trades on a trailing P/E of 51.1. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥4.16 (bear case) to ¥7.72 (bull case); at ¥17.26, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high and 49% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -66%, 301363 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income ¥3.86 ¥4.11 ¥4.54 76
ROIC Compounder ¥4.99 ¥5.88 ¥7.03 72
Growth-Adj P/E ¥4.89 ¥6.98 ¥9.08 68
All 14 models by family
Earnings-Based
Graham-Dodd ¥2.42 ¥7.80 ¥10.41 54
Lynch FV ¥1.74 ¥2.48 ¥3.22 50
PEG = 1.0 ¥1.74 ¥2.48 ¥3.22 46
EPV ¥4.92 ¥5.46 ¥5.92 59
Multiples
P/E Multiple ¥5.87 ¥7.82 ¥9.78 63
P/S Multiple ¥4.53 ¥6.05 ¥7.56 58
P/B Multiple ¥4.53 ¥6.05 ¥7.56 55
EV/EBIT ¥7.15 ¥8.96 ¥10.76 53
EV/EBITDA ¥7.59 ¥9.54 ¥11.50 54
EV/Revenue ¥5.59 ¥7.25 ¥8.91 43
Asset-Based
NCAV (Graham) ¥2.35 ¥3.14 ¥4.69 50
Economic Profit
Residual Income ¥3.86 ¥4.11 ¥4.54 76
ROIC Compounder ¥4.99 ¥5.88 ¥7.03 72
Growth Earnings
Growth-Adj P/E ¥4.89 ¥6.98 ¥9.08 68

Widest divergence: Multiples (¥7.25) versus Earnings-Based (¥2.48). Highest evidence: Residual Income (76).

Key figures & financial health

Revenue (TTM) 1.7B CNY
Revenue growth (YoY) +36.3%
Net margin 16.6%
Return on equity 7.9%
Free cash flow −110M CNY FY2025
P/E ratio 51.1
More key figures
Operating margin 20.0%
EPS (TTM) ¥0.3600
Dividend yield 1.1%
EPS growth (YoY) +11.0%

Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 48/100

Of which business quality 50 · Market factors (momentum, volatility) 44

Profitability 42
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 42
Disciplined investing over empire-building
Low Volatility 41
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 51
Distance to the 52-week high (market factor)
Net Issuance 42
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

MeHow Innovative Ltd. designs, develops, manufactures, and sells precision medical device components and products in China and internationally. The company primarily provides home ventilators, precision molds and automation equipment, surgical instruments, etc.

Full company description

MeHow Innovative Ltd. designs, develops, manufactures, and sells precision medical device components and products in China and internationally. The company primarily provides home ventilators, precision molds and automation equipment, surgical instruments, etc. It also offers variable dose pen, auto injector, auto secure dose pen; microfluidic solutions and laboratory consumables, such as cuvette, PCR tube, 96-well plates, freezing tubes, culture dish and bottle, suction head, and vacutainer; cardiovascular products, including electrophysiology catheter solutions, ablation catheter, high density mapping catheter, and intracardiac echocardiography; surgical solutions, such as ultrasonic scalpels, staplers, ligating clips, sterile-grade/implant-grade injection components, micro precision equipment components, automated assembly, and others. In addition, the company offers ophthalmology and ENT consumables, phacoemulsification disposables, IOL delivery systems, and hearing aids and cochlear implants; respiratory testing equipment and consumables, ventilator consumables, pulmonary function testers, and disposable filters; eternal nutrition infusion sets, nasogastric tube and stoma tube, neuromodulation medical devices, and female reproductive health products; baby and maternity products, consumer electronics, drinking water bottles, personal care, etc. Mehow Innovative Ltd. was founded in 2010 and is headquartered in Shenzhen, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

MeHow Innovative Ltd reported revenue of ¥1.6B in FY2025 versus ¥1.1B in FY2021, a compound +9.3%/yr. Reported net income was ¥283M in FY2025, compounding −2.3%/yr from FY2021.

Growth Quality 55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
1.6B CNY
Latest YoY
+2.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.9%
Revenue +9.3%/yr
FY21 ¥1.1B
FY22 ¥1.4B
FY23 ¥1.3B
FY24 ¥1.6B
FY25 ¥1.6B
Net income −2.3%/yr
FY21 ¥310M
FY22 ¥402M
FY23 ¥313M
FY24 ¥364M
FY25 ¥283M

301363 screens 66% overvalued. Compare with Abbott Laboratories, →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "MeHow Innovative Ltd Fair Value". https://www.fairvalue-calculator.com/stock/301363

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 48 · Below median
Fair Value upside −66% · Bottom 25%
Return on equity (TTM) 8% · Above median
Return on assets 5% · Above median
Net margin (TTM) 17% · Top 25%
Operating margin (TTM) 20% · Top 25%
Revenue growth 36% · Top 25%
Dividend yield (TTM) 1.1% · Below median
Debt / equity 0.02× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 51.1× · Pricier than 75% of peers
P/B 3.92× · Pricier than 75% of peers
P/S (TTM) 8.45× · Pricier than 75% of peers
EV/EBITDA 30.8× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 100 · sector 29
PAST 32 · sector 8
HEALTH 99 · sector 97
DIVIDEND 22 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare MeHow Innovative Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is MeHow Innovative Ltd (301363) overvalued or undervalued?
As of Jul 9, 2026, our model estimates a fair value of ¥5.93 versus a price of ¥17.26, about −66% (overvalued).
What is the fair value of 301363?
Our model-based fair value for MeHow Innovative Ltd is ¥5.93 (as of Jul 9, 2026), built from audited fundamentals. The current price is ¥17.26.
What is the quality score of 301363?
MeHow Innovative Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of MeHow Innovative Ltd (301363)?
MeHow Innovative Ltd reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Jul 9, 2026).
What is the net profit margin of 301363?
The net profit margin of MeHow Innovative Ltd is about 16.6%, meaning it keeps roughly 16.6% of revenue as net income. Based on the latest reported figures.
Does MeHow Innovative Ltd pay a dividend?
MeHow Innovative Ltd currently shows a dividend yield of about 1.08% relative to its recent price (as of Jul 9, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track MeHow Innovative Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.